---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-047158"
form_type: "8-K"
ticker: "VVOS"
cik: "0001716166"
company_name: "Vivos Therapeutics, Inc."
filed_at: "2026-10-15T12:45:26+00:00"
generated_at: "2026-10-15T12:50:17.525608+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Vivos Therapeutics to issue $12M Series C preferred for 11% SOD Sciences stake and 50% test co-ownership

## Summary
- Vivos will issue 12,000 Series C Convertible Preferred shares with $1,000 stated value each, totaling $12 million, to SOD Sciences.
- Consideration includes 2,907,338 SOD common shares, at least 11% fully diluted, and a 50% undivided interest in SOD's pseudohypoxia test IP.
- Series C preferred is convertible at fixed $0.15 per share into up to 80 million common shares, subject to a 19.99% exchange cap.
- Nasdaq minimum $2.5 million stockholders' equity compliance: pro forma equity of about $8 million exceeds requirement by $5.5 million after the deal.
- Closing expected October 15, 2026, subject to independent valuation, auditor concurrence, Streeterville Capital consent, Nasdaq notification, and SOD consents.

## SEC filing metadata
- accession: 0001493152-26-047158
- form_type: 8-K
- ticker: VVOS
- cik: 0001716166
- company_name: Vivos Therapeutics, Inc.
- filed_at: 2026-10-15T12:45:26+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716166/000149315226047158/0001493152-26-047158-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716166/000149315226047158/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-047158
- JSON: https://secwatch.observer/filing/0001493152-26-047158.json
- Plain text: https://secwatch.observer/filing/0001493152-26-047158.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.